320 results on '"Schönermarck, Ulf"'
Search Results
2. Sapovirus: an emerging pathogen in kidney transplant recipients?
3. Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle
4. Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition
5. Thrombotische Mikroangiopathien in der operativen Intensivmedizin unter besonderer Berücksichtigung des atypischen hämolytisch-urämischen Syndroms
6. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
7. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis
8. Klinisches Bild und diagnostisches Vorgehen bei entzündlichen Gefäßerkrankungen
9. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
10. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients
11. Sapovirus – An emerging pathogen in renal transplant recipients?
12. HLA-DRB1∗16 and -DQB1∗05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients
13. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura
14. Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden
15. Large potassium shifts during dialysis enhance cardiac repolarization instability
16. Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation
17. Chronische Nierenerkrankung
18. Autoren
19. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
20. Rituximab in Membranous Nephropathy
21. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
22. Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission
23. Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
24. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
25. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
26. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
27. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
28. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV-patients
29. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
30. Kidney transplantation in ANCA-associated vasculitis
31. Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting
32. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
33. Autoren
34. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
35. Thrombotische Mikroangiopathien in der operativen Intensivmedizin unter besonderer Berücksichtigung des atypischen hämolytisch-urämischen Syndroms
36. Corrigendum: Disqualification of donor and recipient candidates from the living kidney donation program: Experience of a single-center in Germany
37. Autoren
38. SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
39. Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in Germany
40. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
41. Challenges and Considerations in Managing Thrombotic Microangiopathy and Disseminated Intravascular Coagulation in Postpartum Hemorrhage
42. Drug-induced CYP-Induction as Therapy for Tacrolimus Intoxication
43. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients
44. SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
45. HLA-DRB1*16 and -DQB1*05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients
46. Herz oder Nieren? Finden Sie heraus, woran es liegt!
47. Drug-induced CYP-induction as therapy for tacrolimus intoxication
48. The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
49. Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis
50. ANCA Vasculitis Induction Management During the COVID-19 Pandemic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.